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The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is an oncogenic protein which has
previously been shown to engage the NF-B, stress-activated MAP kinase, phosphatidylinositol 3-kinase (PI
3-kinase), and extracellular-regulated kinase (ERK)-MAPK pathways. In this study, we demonstrate that
LMP1 activates ERK-MAPK in epithelial cells via the canonical Raf-MEK-ERK-MAPK pathway but in a
Ras-independent manner. In agreement with the results of a previous study (B. A. Mainou, D. N. Everly, Jr.,
and N. Raab-Traub, J. Virol. 81:9680-9692, 2007), we show that the ability of LMP1 to activate ERK-MAPK
mapped to its CTAR1 domain, the TRAF binding domain previously implicated in PI 3-kinase activation. A role
for ERK-MAPK in LMP1-induced epithelial cell motility was identified, as LMP1-expressing cells displayed
increased rates of haptotactic migration compared to those of LMP1-negative cells. These data implicate the
ERK-MAPK pathway in LMP1-induced effects associated with transformation, suggesting that this pathway
may contribute to the oncogenicity of LMP1 through its ability to promote cell motility and to enhance the
invasive properties of epithelial cells.
Most of what is known about the biology of Epstein-Barr
virus (EBV) relates to its interaction with cells of the B lym-
phoid lineage. EBV was originally identified on the basis of its
association with Burkitt’s lymphoma, and the B lymphotropic
nature of the virus is confirmed by its ability to readily infect
and transform normal resting B cells in vitro (47). The virus,
however, can also infect epithelial cells, and this interaction
can result in malignant transformation, as exemplified by the
consistent association of EBV with nasopharyngeal carcinoma
(NPC) and with a proportion of gastric adenocarcinomas (44,
47, 53). The EBV-induced transformation of B cells in vitro
is associated with the expression of two nonpolyadenylated
RNAs (EBER1 and EBER2), along with a set of latent viral
gene products consisting of six EBV nuclear antigens (EBNA1,
EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA leader
protein) and three latent membrane proteins (LMP1, LMP2A,
and LMP2B) (67). However, more restricted patterns of latent
gene expression are observed in NPC and in EBV-positive
gastric adenocarcinomas, where only the EBERs, EBNA1, and
LMP2A are consistently expressed and the expression of
LMP1 is either variable or absent (44, 67). While the associa-
tion of EBV with various lymphoid and epithelial malignancies
is well documented, the precise contribution of virus infection
to the etiology of these tumors remains unknown.
LMP1 is the major transforming protein of EBV, being
absolutely essential for B-cell transformation (28) and behav-
ing as a classical oncogenic protein in rodent fibroblast trans-
formation assays (61). LMP1 induces the expression of lym-
phocyte activation antigens (62, 63) and antiapoptotic proteins
(Bcl-2, TNFAIP3, and MCL1) (20, 32, 64) and stimulates the
secretion of cytokines such as interleukin-10 (IL-10), among
others (58). When expressed in epithelial cells, LMP1 induces
the expression of IL-6 and IL-8 (10, 12). It can transform
certain established epithelial cell lines and block the terminal
differentiation of the cells (7, 8, 15, 23), and it induces hyper-
keratosis when expressed in transgenic mouse epidermis (65).
LMP1 also induces the expression of the epidermal growth
factor (EGF) receptor (41, 42, 43) and matrix metalloprotein-
ases (35, 54, 59) and can down-regulate the expression of
E-cadherin (16), findings which suggest that LMP1 can mod-
ulate signaling pathways that regulate the motile and invasive
properties of epithelial cells. This characteristic is of particular
relevance given that LMP1-positive NPC tumors are report-
edly more aggressive than their LMP1-negative counterparts
(24).
LMP1 functions as a constitutively activated member of the
tumor necrosis factor receptor superfamily, activating a num-
ber of signaling pathways in a ligand-independent manner (18,
30). LMP1 activates both the canonical and noncanonical
NF-B pathways (37, 49), can induce AP-1 and p38/ATF2
activity (11, 12, 13, 29, 50, 60), and has been shown previously
to activate phosphatidylinositol 3-kinase (PI 3-kinase)/Akt ki-
nase (2, 9, 39).
Although the activation of the NF-B, stress-activated pro-
tein kinase, and PI 3-kinase cascade pathways accounts for
most of the transforming functions of LMP1, additional un-
identified signaling pathways may also participate in LMP1-
mediated growth transformation. In this regard, the activation
of the classical extracellular-regulated kinase (ERK)-MAPK
pathway has been reported to contribute to LMP1-mediated
effects (35). Indeed, a recent study has identified a critical role
for ERK-MAPK in Rat-1 fibroblast transformation by LMP1
(40), underscoring the importance of ERK-MAPK in the on-
cogenic effects of LMP1. The ERK-MAPK family of protein
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kinases regulates many different biological processes by virtue
of their ability to target multiple effector proteins (51). As such
regulators, ERK1 and ERK2 are involved in diverse cellular
processes such as proliferation, differentiation, cytoskeletal re-
modeling, and cell motility. Here, we demonstrate that LMP1
activation of the ERK-MAPK pathway is responsible for
LMP1-induced cell motility and haptotactic migration.
MATERIALS AND METHODS
Cell lines and tissue culture. The human epithelial cell line SCC12F (45) and
a clone of SCC12F cells stably expressing LMP1 were cultured as described
previously (8). HeLa cell clones stably expressing LMP1 have been described
previously (10). A single HeLa MTLM clone was induced to express LMP1 after
the addition of 25 M ZnSO4. HeLa cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 5% fetal calf serum (FCS), 2 mM glutamine,
and a penicillin-streptomycin solution (Sigma) supplemented with 0.5 g of
mycophenolic acid/ml, 25 g of xanthine/ml, and 10 g of hypoxanthine/ml as
previously described (10). Rhek-1 cells and clones stably expressing LMP1 were
cultured as described previously (10).
MDCK cells stably expressing LMP1 and mutant derivatives were generated
by retroviral transduction with pLXSN-based expression vectors containing wild-
type LMP1 (pLXSN-LMP1) or mutant LMP1 proteins defective in the CTAR1
domain (pLXSN-AAA-LMP1), the CTAR2 domain (pLXSN-378stop-LMP1),
or both the CTAR1 and CTAR2 domains (pLXSN-AAA/378Stop-LMP1). These
mutant proteins have been described previously (12). The cell-permeable MEK1
inhibitor U0126 (Promega) was dissolved in dimethyl sulfoxide (DMSO) and
diluted to a final concentration of 30 M. Recombinant human EGF (Sigma)
was used at a final concentration of 100 ng/ml.
Immunoblotting analysis. Standard immunoblotting procedures (9) were used
to detect LMP1 (with mouse CS1-4 at 1:50), phosphorylated ERK1/2 (p-
ERK1/2; with rabbit anti-p-ERK1/2 at 1:1,000 [Cell Signaling Technology]),
ERK-MAPK (with rabbit anti-ERK at 1:1,000 [Cell Signaling Technology]),
phosphorylated Akt (p-AKT; with rabbit anti-p-AKT at 1:1,000 [Cell Signaling
Technology]), Akt (with rabbit anti-Akt at 1:1,000 [Santa Cruz]), phosphorylated
c-Raf (p-c-Raf; with rabbit anti-p-c-Raf at 1:1,000 [Cell Signaling Technology]),
phosphorylated MEK1/2 (p-MEK1/2; with rabbit anti-p-MEK1/2 at 1:1,000 [Cell
Signaling Technology]), phosphorylated p90RSK (p-p90RSK; with rabbit anti-
p-p90RSK at 1:1,000 [Cell Signaling Technology]), and -actin (with mouse
anti--actin at 1:20,000 [Sigma]).
Ras activity assays. Ras activity was assayed using a commercially available kit
according to the instructions of the manufacturer (Upstate Biotechnology).
Briefly, cells were serum starved for 24 h prior to lysis in an NP-40-based lysis
buffer. The total cell lysate (400 g) was immunoprecipitated with a glutathione
S-transferase (GST) fusion protein comprising the Ras binding domain of c-Raf1
for 90 min at 4°C. Immune complexes were subjected to three washes and finally
resuspended in 40 l of gel sample buffer. Samples were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted with an
antibody to Ras. Bound antibody was detected using anti-mouse horseradish
peroxidase-conjugated secondary antibody and visualized by enhanced chemilu-
minescence with a kit from Amersham Biosciences.
Immunofluorescence staining for ERK-MAPK and polymerized actin in ad-
herent cells. Control and LMP1-expressing MDCK cells were cultured in me-
dium containing 0.5% FCS for 24 h prior to recovery as single-cell suspensions
and maintained in suspension for 60 min. Cells (104/100 l) were plated onto
slides coated with fibronectin (10 g/ml) and allowed to adhere for 10 min. After
fixation in 4% paraformaldehyde, cells were permeabilized in 0.5% Triton X-100
(ICN Biochemicals) and stained with antiserum specific for active ERK-MAPK
(Promega) followed by Alexa Fluor 488-conjugated anti-rabbit or anti-mouse
antibodies (Molecular Probes). To visualize cellular actin, fixed and permeabil-
ized cells were incubated with 0.5-g/ml tetramethyl rhodamine isocyanate-
conjugated phalloidin (Sigma) for 60 min. Slides were mounted with DABCO
and viewed at a magnification of400 with a Nikon eclipse E600 microscope and
the Nikon Act-1 program.
Transwell migration assays. Serum-starved cells were recovered as single-cell
suspensions, and 5  104 cells were seeded into the upper well of a transwell
migration chamber (Corning) coated with 10 g of fibronectin/ml. After 16 h of
incubation at 37°C, the wells were fixed in 30% methanol and stained with 1%
crystal violet. The percentage of cell migration was determined after photograph-
ing representative fields and counting the number of stained (migrating) cells.
The extent of cell migration was quantitated by dissolving stained membranes in
0.2% Triton X-100 and measuring the absorbance at 550 nm.
RESULTS
The stable expression of LMP1 results in constitutive acti-
vation of the ERK-MAPK pathway. The ability of LMP1 to
activate the ERK-MAPK pathway in epithelial cell lines stably
expressing LMP1 was investigated. A panel of cell lines includ-
ing Rhek-1 (46), SCC12F (45), and MDCK (38) cells was
examined. The origin and derivation of these cell lines and
their LMP1-expressing counterparts have been detailed else-
where (7, 10). To analyze the effects of LMP1 on ERK-MAPK
activation, cell lysates from serum-starved cells were probed
with an antiserum specific for the dual phosphorylated active
forms of ERK1/2 (p-ERK1/2) (33). Immunoblotting with
LMP1-specific antibodies confirmed the expression of LMP1
only in Rhek-1, SCC12F, and MDCK cells transduced to ex-
press LMP1 (Fig. 1A, B, and C, lower panels). The probing of
the same cell lysates for p-ERK1/2 demonstrated increased
basal ERK1/2 phosphorylation in cells expressing LMP1 (Fig.
1A, B, and C, upper panels) that was comparable to that in
control cells treated with EGF (Fig. 1D). Reprobing of the
immunoblots with antiserum to total ERK1/2 (Fig. 1A, B, and
C, middle panels) confirmed the presence of equal amounts of
ERK1/2 in control and LMP1-expressing cells, excluding the
possibility that the increased basal ERK1/2 phosphorylation
observed in LMP1-expressing cells was due to an increase in
the pool of total ERK1/2. The specificity of ERK1/2 activation
was evidenced by the ability of the U0126 MEK inhibitor to
block both basal and LMP1-induced ERK1/2 phosphorylation
without affecting the levels of either LMP1 or total ERK1/2
(Fig. 1A, B, and C).
Effects of inducible LMP1 expression on the ERK-MAPK
pathway. The constitutively active nature of LMP1 can obscure
the impact of this molecule on cell signaling pathways. To
address this issue, we examined whether ERK1/2 phosphory-
lation occurred in response to transient LMP1 expression in
HeLa cells carrying a metallothionien-regulatable LMP1 gene.
While negligible expression of LMP1 was observed in unin-
duced HeLa MTLM cells, treatment with 25 M ZnSO4 rap-
idly induced LMP1 protein, with peak expression being ob-
served at around 6 h posttreatment (Fig. 2). The probing of the
same cell lysates for p-ERK1/2 confirmed that the activation of
ERK1/2 coincided temporally with the induction of LMP1 and
that LMP1 expression did not increase the total amount of
ERK1/2.
To examine whether the ability of LMP1 to activate ERK1/2
followed the canonical Raf-MEK-ERK-MAPK pathway, the
same panel of lysates from induced and uninduced HeLa
MTLM cells were subjected to immunoblotting with antiserum
specific for the phosphorylated forms of c-Raf and MEK1/2.
The activation of ERK1/2 in the canonical ERK-MAPK cas-
cade involves the activation of Ras by tyrosine kinase-coupled
growth factor receptors (50). Once activated, Ras recruits and
activates the upstream MAPK kinase kinase (MAPKKK) c-
Raf, which in turn phosphorylates and activates the MAPK
kinase MEK. As shown in Fig. 2, the induced expression of
LMP1 resulted in the phosphorylation of both c-Raf (observed
as a significant mobility shift in the c-Raf protein) and
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MEK1/2. Interestingly, the maximal phosphorylation of c-Raf
did not coincide temporally with the phosphorylation of
MEK1/2 or ERK1/2, indicating that c-Raf activation may not
be involved in the first wave of MEK-ERK-MAPK activation.
The phosphorylation of p90RSK, a putative downstream target
of ERK1/2, mirrored that of ERK1/2, providing evidence that
the ERK1/2 induced by LMP1 is functionally active.
LMP1 activation of the ERK-MAPK pathway is indepen-
dent of Ras. Given the slight discrepancy in c-Raf, MEK, and
ERK-MAPK phosphorylations, we next sought to examine the
effects of LMP1 on c-Ras activity. In the canonical Raf-MEK-
ERK pathway, the Ras small GTPase activates ERK-MAPK
by engaging c-Raf. We examined the effect of LMP1 on Ras
activity by using an immunoprecipitation assay with a GST
fusion protein comprising the Ras binding domain of c-Raf.
The presence of “active” Ras was determined by probing im-
munoprecipitates with a Ras-specific antibody. As a specificity
control, lysates were treated with the nonhydrolyzable ana-
logue of GTP, GTPS, and excess GDP to activate and inhibit
Ras activity, respectively. As shown in Fig. 3 (lower panel),
lysates from control cells treated with GTPS showed in-
creased Ras activity whereas this activity was completely abol-
ished in SCC12F and Rhek-1 lysates treated with a 100-fold
excess of GDP; GDP treatment of MDCK lysates reduced
rather than abolished Ras activity. The analysis of lysates from
control and LMP1-expressing cells revealed that the levels of
Ras activity were consistently lower in all epithelial cell lines
expressing LMP1. Ras expression levels in control and LMP1-
expressing epithelial cells were similar (Fig. 3, middle panel),
ruling out the possibility that LMP1 expression was associated
with reduced levels of the Ras protein.
LMP1 induces ERK-MAPK through the proximal TRAF
binding domain, CTAR1. To gain further insight into the
mechanism by which LMP1 induces the activation of the ERK-
MAPK pathway, we sought to identify which domain of LMP1
was responsible for this activation. MDCK cells stably express-
ing wild-type LMP1 and LMP1 mutant proteins defective in
the CTAR1 domain (AAA-LMP1), the CTAR2 domain
(378stop-LMP1), or both domains (AAA/378stop-LMP1) (12)
were generated by retroviral transduction. Immunoblot analy-
ses confirmed that wild-type and mutant LMP1 proteins were
expressed in all transduced cells at broadly similar levels (Fig.
4A). To examine which of the LMP1 mutant proteins was
responsible for ERK-MAPK activation, total cell lysates from
serum-starved cells were subjected to immunoblotting for
p-ERK1/2. This analysis confirmed the ability of wild-type
LMP1 to activate the ERK-MAPK pathway in MDCK cells
and identified the CTAR1 domain of LMP1 as being respon-
sible for this activation. Only minimal levels of p-ERK1/2 were
observed in AAA-LMP1-expressing cells, whereas cells ex-
pressing 378stop-LMP1 had levels of p-ERK1/2 comparable to
those observed in cells expressing wild-type LMP1 (Fig. 4A).
As expected, cells expressing AAA/378stop-LMP1 showed
only low levels of ERK1/2 phosphorylation, ruling out contri-
butions of the amino terminus and transmembrane-spanning
regions of LMP1 to this effect. Reprobing with an antibody to
ERK1/2 demonstrated the presence of equal amounts of these
proteins in all cell lines, confirming that LMP1 expression does
not influence the levels of ERK1/2 protein expression.
The probing of the same panel of cell lysates with antiserum
specific for p-Akt demonstrated that the CTAR1 domain of
LMP1, in addition to activating ERK-MAPK, is responsible for
engaging the PI 3-kinase/Akt pathway. High levels of serine
473-phosphorylated Akt compared to levels in control MDCK
cells were observed only in MDCK cells expressing wild-type
LMP1 and 378stop-LMP1 proteins (Fig. 4A). Control EGF-
treated MDCK cells were used as a positive control and dis-
FIG. 1. Stable LMP1 expression induces the constitutive activation
of ERK1/2 in LMP1-expressing epithelial cell lines. (A to C) Immu-
noblot analyses demonstrating the expression of p-ERK1/2 (upper
panels), total ERK1/2 (middle panels), and LMP1 (lower panels) in
control and LMP-expressing cells in the presence ( U0126) or ab-
sence (untreated) of the MEK inhibitor U0126. Representative anal-
yses for SCC12F (A), Rhek-1 (B), and MDCK (C) cells are shown.
(D) Rhek-1, SCC12F, and MDCK cells stimulated with EGF () or
left untreated () were included as a positive control. The increases
(n-fold) in ERK-MAPK phosphorylation are indicated in parentheses.
Numbers on the left of the blots are molecular weight markers. p-p44,
phosphorylated p44; p-p42, phosphorylated p42.
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played high levels of serine 473-phosphorylated Akt. Reprob-
ing with an antibody to Akt confirmed the presence of equal
amounts of Akt protein in all cell lines (Fig. 4A).
The specificity of wild-type LMP1- and 378stop-LMP1-in-
duced ERK1/2 phosphorylation was established using the
U0126 MEK inhibitor. Whereas the treatment of parental
MDCK cells and MDCK cells expressing wild-type and mutant
LMP1 proteins with DMSO had no effect on the ability of
wild-type LMP1 or the 378stop LMP1 mutant form to induce
ERK-MAPK phosphorylation, treatment with 20 M U0126
significantly inhibited this activation; the effect on ERK1 phos-
phorylation appeared to be more dramatic than that on ERK2
phosphorylation (Fig. 4B). The specificity of this effect was
confirmed by the inability of SB203850, a selective cell-perme-
able inhibitor of p38, to influence LMP1-induced ERK1/2
phosphorylation (Fig. 4B). The probing of the immunoblots
with an antibody to ERK1/2 confirmed the loading of equal
amounts of protein (Fig. 4B).
LMP1-induced ERK-MAPK activation promotes epithelial
cell motility and invasion. In addition to their role in cell
proliferation, members of the ERK-MAPK family regulate
epithelial cell motility and invasion (57). ERK1 and ERK2
regulate cell movement by coordinating actin filament dynam-
ics and focal adhesion turnover. Putative targets of ERK1/2
action are myosin light-chain kinase and a focal adhesion-
associated calpain that regulates focal adhesion stability by
FIG. 2. LMP1 activates ERK1/2 via MEK in HeLa MTLM cells. Immunoblot analyses demonstrated the expression of LMP1, p-ERK1/2,
ERK1/2, p-c-Raf, p-MEK1/2, and p-p90RSK in HeLa MTLM cells induced to express LMP1 (HeLa-LMP1) after the addition of 25 M ZnSO4.
HeLa cells stimulated with EGF (100 ng/ml) were included as a positive control. The increases (n-fold) in ERK-MAPK, c-Raf, MEK1/2, and
p90RSK phosphorylation are indicated in parentheses. p-p44, phosphorylated p44; p-p42, phosphorylated p42.
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cleaving focal adhesion kinase (25, 57). Additionally, ERK1
and ERK2 regulate the production and secretion of matrix
metalloproteinase and the remodeling of the extracellular ma-
trix (7). In a previous study, Li and colleagues demonstrated a
role for ERK-MAPK in LMP1-mediated cell invasion through
the increase of matrix metalloproteinase production (35). As
this study had highlighted an ability of LMP1 to promote
epithelial cell invasion through the extracellular matrix (35),
we next examined whether LMP1 could promote the migration
of MDCK cells and determined whether the ERK-MAPK
pathway was required for this process. In this assay, the ability
of cells to migrate through a fibronectin-coated polycarbonate
membrane was assayed under serum-free conditions to exclude
any contributions from soluble growth factors or cytokines.
Results from a representative experiment depicted in Fig. 5A
show that LMP1-expressing MDCK cells displayed signifi-
cantly higher rates of haptotactic migration than control
LMP1-negative cells over 16 h, and this finding was confirmed
in triplicate assays (Fig. 5B). The ability of LMP1 to promote
migration mapped, like ERK-MAPK activation, to the CTAR1
domain (Fig. 4). Thus, MDCK cells expressing the 378stop-
LMP1 mutant protein displayed significantly higher rates of
migration than either control cells or cells expressing either
AAA-LMP1 or AAA/378stop-LMP1 (Fig. 5).
Active ERK-MAPK is translocated to the leading edges of
adhering epithelial cells. As ERK-MAPK activity appeared to
be essential for LMP1 to enhance cell migration and invasion,
we next examined whether membrane targeting of ERK-
MAPK occurred in response to cell adhesion. MDCK cells
expressing wild-type or mutant LMP1 proteins were serum
starved for 16 h, recovered as single-cell suspensions, and
plated onto fibronectin-coated slides. Ten minutes after plating,
cells were fixed and stained with a polyclonal rabbit antiserum
specific for active ERK-MAPK (Promega) or rhodamine-con-
jugated phalloidin to visualize actin filament reorganization.
MDCK cells expressing wild-type LMP1 or 378stop-LMP1
showed increased rates of attachment, and spreading onto
fibronectin and immunostaining revealed increased amounts
of active p-ERK-MAPK in lamellapodia at the leading
edges of spreading cells (Fig. 6A). The staining of the same
cells with phalloidin (Fig. 6B) demonstrated robust actin
stress fiber formation in wild-type LMP1- and 378stop-
LMP1-expressing cells, indicating ERK-MAPK-mediated
cytoskeletal remodeling.
To examine the effects of ERK-MAPK inhibition on these
responses, cells were resuspended in serum-free medium
containing 20 M U0126 for 60 min prior to being plated
onto fibronectin. Results from a representative experiment
presented in Fig. 6C show that ERK-MAPK inhibition,
while not inhibiting cell attachment per se, had a profound
effect on cell spreading. U0126 treatment severely impaired
the membrane targeting of active ERK-MAPK in LMP1-
expressing cells, with ERK-MAPK localizing to large focal
adhesions at protrusive sites at the cell membrane. This
pattern was in marked contrast to that in untreated cells,
where active ERK-MAPK was uniformly distributed at the
leading edges of spreading cells.
FIG. 3. LMP1 does not stimulate endogenous c-Ras activity. (A) SCC12F, Rhek-1, and MDCK cells or their LMP1-expressing counterparts
were cultured in medium containing 0.5% FCS for 24 h prior to analysis. Equal amounts of total cell lysates (300 g) were subjected to
immunoprecipitation with a GST fusion protein containing the Ras binding domain of c-Raf. The levels of active GTP-bound Ras were determined
after immunoblotting of the immunoprecipitates with a monoclonal antibody to Ras (upper panel). The increases (n-fold) in c-Ras activity are
indicated in parentheses. Immunoblotting of total cell lysates from control (con.) and LMP1-expressing cells with an antibody to Ras confirmed
the presence of equal amounts of endogenous Ras in control and LMP1-expressing cells (middle panel). As an internal assay control, lysates
generated from control SCC12F, Rhek-1, and MDCK cells were treated with GTPS or a 100-fold excess of GDP to activate or inhibit endogenous
Ras activity, respectively (lower panel). Numbers on the left of the blots are molecular weight markers.
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DISCUSSION
The oncogenic properties of LMP1 are a consequence of its
ability to constitutively engage signaling pathways that impact
different cellular processes, including cell growth, survival, and
differentiation. While previous work has clearly defined the
contributions of the NF-B, Jun N-terminal protein kinase/
p38, and PI 3-kinase pathways to these effects, the role of the
ERK-MAPK pathway in the oncogenic effects of LMP1 has,
until recently, remained controversial. Mainou and colleagues
have recently identified a role for ERK-MAPK in the LMP1-
mediated transformation of Rat-1 fibroblasts in vitro (40). In
epithelial cells, LMP1 activation of the ERK-MAPK pathway
appears to be cell type specific. In an early study, LMP1 failed
to induce ERK-MAPK activation in 293 kidney epithelial cells
(29), whereas studies performed with squamous epithelial cells
have demonstrated an ability of LMP1 to engage the ERK-
MAPK pathway (35, 36). We set out to more carefully define
the contribution of LMP1 to ERK-MAPK activation and have
found that this pathway has profound phenotypic effects con-
sistent with the oncogenic function of LMP1.
Our data confirm and extend results from previous studies
showing that LMP1 promotes the invasive growth of canine
(MDCK) and human (NP-69 and TW04) epithelial cell lines
(31, 35, 36). In addition to demonstrating an ERK-MAPK-
dependent effect of LMP1 on cell motility and invasion, we
have partly delineated the mechanism by which LMP1 acti-
vates the ERK-MAPK pathway and have identified the do-
main of LMP1 responsible for this activation. Using phos-
phorylation state-specific antiserum recognizing the
phosphorylated form of active ERK1/2 (p-ERK1/2), we
showed that the basal level of ERK1/2 activity was signifi-
cantly elevated in a number of epithelial cell lines stably
expressing LMP1. That this activity was not due to the
effects of long-term LMP1 expression was supported by
findings showing that ERK-MAPK activity was induced in
response to the transient expression of LMP1. Although we
did not perform in vitro kinase assays to assess ERK1/2
activity, numerous studies have demonstrated a strong cor-
relation between ERK1/2 phosphorylation, the nuclear
translocation of ERK1/2, and increased ERK-MAPK activ-
ity (19, 34). Further confirmation that LMP1-induced
ERK1/2 phosphorylation was associated with increased
ERK1/2 activity was established as p90RSK, a putative
downstream target of ERK1/2, was phosphorylated in re-
sponse to LMP1 expression. While these data suggest that
LMP1 activates ERK-MAPK signaling directly, an indirect
contribution from LMP1-induced effects such as the secre-
tion of soluble cytokines or growth factors or the modula-
tion of adhesion receptor signaling cannot be excluded.
Although our studies clearly demonstrate that LMP1 is able
to activate the ERK-MAPK pathway in epithelial cells, the
mechanism(s) involved in this activation is still unresolved.
Many growth factor (receptor tyrosine kinase) and adhesion
receptors recruit adapter molecules (SHC and Grb2) to the
“activated” receptor complex, which couples the receptors to
the Ras small GTPase. Ras then binds to and sequentially
activates c-Raf (a MAPKKK) and MEK1/2 (a MAPK kinase),
culminating in ERK-MAPK activation. Using phosphorylation
FIG. 4. The CTAR1 domain of LMP1 is responsible for ERK-MAPK and Akt activation. (A) Immunoblot analyses of MDCK control cells and
cells expressing wild-type and mutant LMP1 proteins for LMP1 (upper panel), p-ERK1/2 (upper middle panel), total ERK1/2 (middle panel),
p-Akt (lower middle panel), and Akt (bottom panel). Control cells stimulated with 100 ng of EGF/ml for 5 min were included as positive controls.
The increases (n-fold) in ERK-MAPK and Akt phosphorylation are indicated in parentheses. p-p44, phosphorylated p44; p-p42, phosphorylated
p42. (B) Control and LMP1-expressing cells were cultured in medium containing 0.5% FCS and either a vehicle control (DMSO) (upper panel),
20 M U0126 (upper middle panel), or 20 M SB203580 (lower middle panel) for 24 h prior to being probed with antiserum specific for p-ERK1/2
or total ERK1/2 (bottom panel). The decreases (n-fold) in ERK-MAPK phosphorylation are indicated in parentheses.
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state-specific antiserum, we were able to demonstrate that in
the inducible HeLa MTLM cell system, c-Raf and MEK1/2
phosphorylation coincided temporally with the induction of
LMP1. These findings, coupled with our ability to block
LMP1-induced ERK1/2 phosphorylation with U0126, a spe-
cific inhibitor of MEK1/2, strongly support the notion that
LMP1 induces ERK1/2 activation through MEK1/2. How-
ever, we were unable to identify a role for Ras activation in
this phenomenon, which is surprising given that dominant-
negative N17Ras has previously been shown to block the
ability of LMP1 to transform Rat-1 fibroblasts (48). This
result suggests that in LMP1-expressing epithelial cells, as
opposed to rodent fibroblasts, the ability of LMP1 to engage
the ERK-MAPK pathway involves Ras-independent activa-
tion of c-Raf. Such a scenario is not without precedent, as
Ras-independent activation of c-Raf has been reported pre-
viously and can be mediated via either classical and atypical
protein kinase C isoforms or certain classes of receptor
tyrosine kinases (4, 5, 52). Alternatively, c-Raf may not be
the only upstream MAPKKK responsible for LMP1-medi-
ated MEK1/2 activation. Previous work from our laboratory
has identified a role for the serine/threonine kinase Tpl-2 in
LMP1-mediated NF-B activation (14), and as Tpl-2 can
also couple with the ERK-MAPK pathway (6), it is possible
FIG. 5. MDCK cells expressing LMP1 show increased rates of motility in transwell migration assays. (A) MDCK control cells and cells
expressing wild-type (WT) and mutant LMP1 proteins were seeded (in triplicate) into fibronectin-coated transwell chambers. Sixteen hours after
plating, the number of migrating cells was determined by visualization after fixation and staining with 1% crystal violet. Representative membranes
are shown. Magnification, 100. (B) Sixteen hours after plating, the number of cells migrating through the fibronectin-coated polycarbonate
membrane was determined after fixation and staining with 1% crystal violet. After solubilization in 0.1% Triton X-100, the relative number of
migrated cells was evaluated by measuring the absorbance at 595 nm. Data presented are the averages of triplicate results. Error bars indicate
standard deviations.
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that this kinase mediates the ability of LMP1 to activate the
ERK-MAPK cascade by directly phosphorylating MEK1/2.
Other oncogenic herpesviruses encode terminal mem-
brane proteins that activate ERK-MAPK, suggesting that
this pathway is important for the virus life cycle and that
aberrant or inappropriate activation contributes to tumori-
genesis. Thus, the herpesvirus saimiri-encoded StpC protein
engages the ERK-MAPK pathway via binding to Ras (27),
while the Kaposi’s sarcoma-associated herpesvirus-encoded
K15 membrane protein activates this pathway through
mechanisms involving src family kinases and TRAF2 (3). It
is thus possible that TRAF2 mediates the ability of LMP1 to
FIG. 6. LMP1 promotes ERK translocation to the leading edges of adhering cells. (A) MDCK control cells and cells expressing wild-type (WT)
or mutant LMP1 protein were plated onto fibronectin, and after fixation, adherent cells were immunostained with an antiserum to active
ERK-MAPK. (B) Cells were analyzed as described for panel A except that they were stained with tetramethyl rhodamine isocyanate-conjugated
phalloidin to visualize polymerized actin. (C) Cells were analyzed as described for panel A except that MDCK control cells and cells expressing
wild-type LMP1 were plated onto fibronectin in the presence (U0126) or absence (U0126) of 20 M U0126 and stained for active
p-ERK-MAPK. Magnification, 400.
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activate ERK-MAPK and that this may be a consequence of
the ability of TRAF2 to interact with Tpl-2, a complex we
have previously shown to be important for LMP1-induced
NF-B activation (6, 14). The expression of LMP1 in
TRAF2-deficient murine fibroblasts or B cells results in
normal levels of NF-B activation, suggesting that the in-
teraction of TRAF2 with LMP1 is not essential for the
NF-B pathway but may be responsible for engaging other
signaling pathways (37, 66). In agreement with the results of
a study by Mainou and colleagues (40), we found that the
LMP1-induced activation of ERK-MAPK maps to the
CTAR1 domain of LMP1, and thus, it may be that the
interaction of TRAF2 with this site mediates this effect.
Future studies using knockout murine cells as well as RNA
interference approaches will directly address the role of
TRAF2 and Tpl-2 in LMP1-induced ERK-MAPK activa-
tion.
Although ERK-MAPK activation is associated with prolif-
erative responses in most cell types, ERK-MAPK also func-
tions to regulate cell motility and migration (25, 56). In this
study, we demonstrate that the ability of LMP1 to activate
ERK-MAPK is both necessary and sufficient to promote cell
spreading, motility, and haptotactic migration. In transwell mi-
gration assays, LMP1-expressing MDCK cells showed in-
creased rates of motility and migrated through a fibronectin
matrix more efficiently than control cells.
We also demonstrate that the CTAR1 domain of LMP1 is
responsible for these effects, as both wild-type LMP1 and
the CTAR1-positive mutant form (378stop-LMP1) not only
induced ERK-MAPK activity but also promoted the intra-
cellular targeting of active ERK-MAPK to newly formed
focal adhesions and lamellapodia in adhering cells. That the
membrane targeting of ERK-MAPK is important for LMP1-
induced effects on cell spreading and motility was borne out
by our finding that U0126 treatment severely inhibited
ERK-MAPK translocation to membrane ruffles and pre-
vented efficient cell spreading. As cell spreading relies on
the activity of the small Rho GTPases, this effect is most
likely attributed to the inhibition of Rac GTPase activity, an
established target of ERK-MAPK that is known to promote
membrane ruffling and cell motility (1, 56).
Previous work has implicated integrin engagement and the
activation of c-src in the plasma membrane targeting of acti-
vated ERK-MAPK to focal adhesions, suggesting that the ef-
fects of LMP1 may be mediated through these pathways (17).
Future studies will determine whether LMP1 induces ERK-
MAPK activity directly, through the direct binding of effector
molecules that engage the ERK-MAPK pathway, or induces
this pathway indirectly by altering the activation state of inte-
grins, so-called “inside-out” signaling.
As deregulated integrin signaling is associated with con-
stitutive ERK-MAPK activation and this contributes to ab-
errant growth and differentiation (19, 21, 22), it is possible
that LMP1 induces a hyperkeratotic state and perturbs ke-
ratinocyte differentiation by disrupting normal integrin sig-
naling. Indeed, deregulated or constitutive ERK-MAPK sig-
naling plays an important role in the pathogenesis of many
epithelial disorders and is implicated in the etiology of both
benign and malignant epithelial diseases. In these disorders,
ERK-MAPK is chronically activated as a result of overex-
pression or deregulated signaling from certain classes of
integrin receptors (26). As many of these features are char-
acteristic of epithelial cells expressing LMP1 (7, 8, 65), the
possibility that some of these phenotypic effects are the
result of the chronic activation of the ERK-MAPK pathway
clearly warrants further examination. Whether this results
from the effects of LMP1 on integrin receptor signaling is
presently unknown, although our unpublished observations
suggest that LMP1 does indeed modulate integrin receptor
expression and signaling in human keratinocytes. Whatever
the underlying mechanism, the ability of LMP1-induced
ERK-MAPK activation to promote cell motility and migra-
tion is likely to have clinically relevant consequences and
may account for the observation that LMP1-positive NPC
tumors are both more aggressive and more metastatic than
their LMP1-negative counterparts. The clinical develop-
ment of ERK-MAPK (MEK) inhibitors is a focus of much
interest, particularly in conjunction with genetic-based pa-
tient selection (e.g., B-raf mutations). Such inhibitors may
also be of clinical benefit in the context of LMP1-positive
EBV-associated tumors.
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